Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition
- 284 Downloads
The molecular mechanisms associated with prostate cancer (PCa) progression within bone remain a topic of intense investigation. With the availability of transgenic mouse strains, a model of PCa for use in immune competent/transgenic mice would be highly beneficial. This study was designed to explore the utility of RM1 mouse PCa cells in investigations of tumor:bone interactions. The efficacies of several implantation techniques were examined for reliably producing intra-bone RM1 tumor growth and bone lesion formation in immune competent mice. Longitudinal monitoring of bone remodeling and lesion phenotypes was conducted by microcomputed tomography (μCT) and histological analyses. Our results indicate that direct intrabone injections of RM1 cells are necessary for tumor growth within bone and direct implantation promotes the rapid development of osteolytic bone lesions with periosteal bone deposition post-cortical breach. In vitro, RM1 cells promote the proliferation of osteoblast (MC3T3-E1) and osteoclast (Raw264.7) progenitors in a dose dependent manner. Conditioned culture media from RM1 cells appears to promote earlier expression of genes/proteins associated with osteoblastic differentiation. While clearly stimulating osteoclast function in vivo, RM1 cells had little effect on differentiation and tartate resistant acid phosphatase (TRAP) expression by Raw264.7 cells. These data, coupled with in vivo μCT images, indicate the ability of RM1 cells to induce mixed, yet predominentally osteolytic, responses in bone and illustrate the potential of RM1 cells as a model of investigating prostate tumor:stroma interactions in immune competent/transgenic mice on a C57BL/6 background.
KeywordsProstate cancer Bone Animal model Osteolytic Osteoblastic
This work was supported by the following grants: DK060933/CA126847 to T.V. Byzova. N.P. McCabe is supported by a Ruth L. Kirschstein Research Service Award (NRSA) Individual Fellowship (5F32CA1172462); Cleveland Clinic Musculoskeletal Core Center funded in part by NIAMS Core Center Grant 1P30 AR-050953.
- 1.American Cancer Society (2007) Cancer facts & figures 2007. American Cancer Society, Inc., AtlantaGoogle Scholar
- 2.Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594. doi: 10.1002/(SICI)1097-0142(19971015)80:8±≤1588::AID-CNCR9≥3.0.CO;2-G PubMedCrossRefGoogle Scholar
- 6.Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61–69. doi: 10.1016/S0925-4773(00)00551-7 PubMedCrossRefGoogle Scholar
- 10.Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL (2001) Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 93:998–1007. doi: 10.1093/jnci/93.13.998 PubMedCrossRefGoogle Scholar
- 14.Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A (2001) Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61:2177–2182PubMedGoogle Scholar
- 22.Henry MD, Silva MD, Wen S, Siebert E, Solin E, Chandra S, Worland PJ (2005) Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients. Prostate 65:347–354. doi: 10.1002/pros.20300 PubMedCrossRefGoogle Scholar
- 26.Martinez J, Silva S, Santibanez JF (1996) Prostate-derived soluble factors block osteoblast differentiation in culture. J Cell Biochem 61:18–25. doi: 10.1002/(SICI)1097-4644(19960401)61:1≤18::AID-JCB3≥3.0.CO;2-5 PubMedCrossRefGoogle Scholar